scholarly journals Cationic Albumin Nanoparticles for Enhanced Drug Delivery to Treat Breast Cancer: Preparation and In Vitro Assessment

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Sana Abbasi ◽  
Arghya Paul ◽  
Wei Shao ◽  
Satya Prakash
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Serum Albumin ◽  
Anticancer Drugs ◽  
Antineoplastic Agent ◽  
In Vitro Assessment ◽  
Nanoparticle Formulation ◽  
Treat Breast Cancer ◽  
Effective Carrier

Most anticancer drugs are greatly limited by the serious side effects that they cause. Doxorubicin (DOX) is an antineoplastic agent, commonly used against breast cancer. However, it may lead to irreversible cardiotoxicity, which could even result in congestive heart failure. In order to avoid these harmful side effects to the patients and to improve the therapeutic efficacy of doxorubicin, we developed DOX-loaded polyethylenimine- (PEI-) enhanced human serum albumin (HSA) nanoparticles. The formed nanoparticles were ~137 nm in size with a surface zeta potential of ~+15 mV, prepared using 20 μg of PEI added per mg of HSA. Cytotoxicity was not observed with empty PEI-enhanced HSA nanoparticles, formed with low-molecular weight (25 kDa) PEI, indicating biocompatibility and safety of the nanoparticle formulation. Under optimized transfection conditions, approximately 80% of cells were transfected with HSA nanoparticles containing tetramethylrhodamine-conjugated bovine serum albumin. Conclusively, PEI-enhanced HSA nanoparticles show potential for developing into an effective carrier for anticancer drugs.

scholarly journals The Therapeutic Efficacy of Dendrimer and Micelle Formulations for Breast Cancer Treatment

Pharmaceutics ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 1212
Author(s):  
Sibusiso Alven ◽  
Blessing Atim Aderibigbe
Keyword(s):  
Breast Cancer ◽  
Drug Delivery ◽  
Drug Resistance ◽  
Side Effects ◽  
Anticancer Drugs ◽  
Drug Toxicity ◽  
Multi Drug Resistance ◽  
Drug Bioavailability

Breast cancer is among the most common types of cancer in women and it is the cause of a high rate of mortality globally. The use of anticancer drugs is the standard treatment approach used for this type of cancer. However, most of these drugs are limited by multi-drug resistance, drug toxicity, poor drug bioavailability, low water solubility, poor pharmacokinetics, etc. To overcome multi-drug resistance, combinations of two or more anticancer drugs are used. However, the combination of two or more anticancer drugs produce toxic side effects. Micelles and dendrimers are promising drug delivery systems that can overcome the limitations associated with the currently used anticancer drugs. They have the capability to overcome drug resistance, reduce drug toxicity, improve the drug solubility and bioavailability. Different classes of anticancer drugs have been loaded into micelles and dendrimers, resulting in targeted drug delivery, sustained drug release mechanism, increased cellular uptake, reduced toxic side effects of the loaded drugs with enhanced anticancer activity in vitro and in vivo. This review article reports the biological outcomes of dendrimers and micelles loaded with different known anticancer agents on breast cancer in vitro and in vivo.

scholarly journals New insights on CRISPR/Cas9-based therapy for breast Cancer

2021 ◽  
Vol 43 (1) ◽  
Author(s):  
Hussein Sabit ◽  
Shaimaa Abdel-Ghany ◽  
Huseyin Tombuloglu ◽  
Emre Cevik ◽  
Amany Alqosaibi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Research ◽  
Animal Models ◽  
Human Cancer ◽  
Step Process ◽  
Cancer Initiation ◽  
Malignant State ◽  
Treat Breast Cancer

AbstractCRISPR/Cas9 has revolutionized genome-editing techniques in various biological fields including human cancer research. Cancer is a multi-step process that encompasses the accumulation of mutations that result in the hallmark of the malignant state. The goal of cancer research is to identify these mutations and correlate them with the underlying tumorigenic process. Using CRISPR/Cas9 tool, specific mutations responsible for cancer initiation and/or progression could be corrected at least in animal models as a first step towards translational applications. In the present article, we review various novel strategies that employed CRISPR/Cas9 to treat breast cancer in both in vitro and in vivo systems.

scholarly journals Breast Cancer Chemotherapeutic Options: A General Overview on the Preclinical Validation of a Multi-Target Ruthenium(III) Complex Lodged in Nucleolipid Nanosystems

Cells ◽  
2020 ◽  
Vol 9 (6) ◽  
pp. 1412
Author(s):  
Maria Grazia Ferraro ◽  
Marialuisa Piccolo ◽  
Gabriella Misso ◽  
Francesco Maione ◽  
Daniela Montesarchio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Anticancer Drugs ◽  
Anticancer Agents ◽  
Preclinical Development ◽  
Cell Death Pathways ◽  
Complex Information ◽  
Ru Complexes ◽  
Therapeutic Alternatives

In this review we have showcased the preclinical development of original amphiphilic nanomaterials designed for ruthenium-based anticancer treatments, to be placed within the current metallodrugs approach leading over the past decade to advanced multitarget agents endowed with limited toxicity and resistance. This strategy could allow for new options for breast cancer (BC) interventions, including the triple-negative subtype (TNBC) with poor therapeutic alternatives. BC is currently the second most widespread cancer and the primary cause of cancer death in women. Hence, the availability of novel chemotherapeutic weapons is a basic requirement to fight BC subtypes. Anticancer drugs based on ruthenium are among the most explored and advanced next-generation metallotherapeutics, with NAMI-A and KP1019 as two iconic ruthenium complexes having undergone clinical trials. In addition, many nanomaterial Ru complexes have been recently conceived and developed into anticancer drugs demonstrating attractive properties. In this field, we focused on the evaluation of a Ru(III) complex—named AziRu—incorporated into a suite of both zwitterionic and cationic nucleolipid nanosystems, which proved to be very effective for the in vivo targeting of breast cancer cells (BBC). Mechanisms of action have been widely explored in the context of preclinical evaluations in vitro, highlighting a multitarget action on cell death pathways which are typically deregulated in neoplasms onset and progression. Moreover, being AziRu inspired by the well-known NAMI-A complex, information on non-nanostructured Ru-based anticancer agents have been included in a precise manner.

scholarly journals Human serum albumin-mediated apoptin delivery suppresses breast cancer cell growth in vitro and in vivo

2016 ◽  
Vol 13 (2) ◽  
pp. 579-586 ◽  
Author(s):  
Fang Wu ◽  
Yizhi Liu ◽  
Jian Li ◽  
Lei Hou ◽  
Fuxi Lei ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cell Growth ◽  
Human Serum Albumin ◽  
Serum Albumin ◽  
Human Serum ◽  
Breast Cancer Cell ◽  
Cancer Cell Growth ◽  
Breast Cancer Cell Growth

scholarly journals EMERGING BIOSIMILARS IN ONCOLOGY: A REVIEW

2018 ◽  
Vol 11 ◽  
Author(s):  
Lavanya B
Keyword(s):  
Breast Cancer ◽  
Amino Acids ◽  
Developing Countries ◽  
Cardiovascular Diseases ◽  
Side Effects ◽  
Experimental Studies ◽  
Therapeutic Effects ◽  
Medicinal Products ◽  
The Us

Biosimilars are the biological medicinal products that produce the therapeutic effects in the human body similar to that of inner biological molecule. Biopharmaceuticals consist of nucleic acids, amino acids, polysaccharides, or combination of all compounds. In India, the steps have been taken to manufacture biosimilars with the lowest cost and least side effects. Globally, India is one of the major developing countries in manufacturing and marketing of biosimilars. The application of biosimilar was rapidly growing in treating various disorders such as cancer, inflammatory disease, and cardiovascular diseases. For the approval of biosimilars, in vitro studies become the necessity for representing comparison to a standard biological in terms of quality for experimental studies indicating similar pharmacokinetics, efficacy, safety, and immunogenicity. Huminsulin was the first DNA-recombinant protein accepted by the US Food and Drug Administration (FDA) in 1982. As currently there are no FDA-approved biosimilars for treating breast cancer, many biologic antibodies are under investigation.

Chlorambucil-Chitosan Nano-conjugate: An efficient Agent against Breast Cancer Targeted Therapy

2020 ◽  
Vol 17 ◽  
Author(s):  
Azadeh Shayegh ◽  
Farinaz Khalatbari ◽  
Niloofar Zonoubi ◽  
Farjad Zarazvand ◽  
Fatemeh Monavvari ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Side Effects ◽  
Biological Effects ◽  
Rt Pcr ◽  
Chemotherapy Drugs ◽  
Anti Cancer ◽  
Afm Analysis ◽  
Cancer Targeted Therapy ◽  
Mcf 7

Background: Discovering new chemotherapy drugs and techniques with the least side effects is one of the most important and challenging world issues in recent years. Chlorambucil is an anticancer drug that is still commonly used as a primary treatmentin at treatment of some cancers, but it can cause side effects. Objective: In this study, we decided to use chitosan as a carrier for enhance the uptake of chlorambucil and reduce the toxicity of this drug. Method: After producing this nanoconjugate compound and analysing its structure by FTIR, DLS and AFM analysis, we investigated the therapeutic and biological effects of this nanoconjugate compound on the MCF-7 cell line (breast cancer). Results: The results of the MTT assay showed that this nanoconjugate compound not only retained its anti-cancer effect against chlorambucil but also showed less abnormal toxicity. Also, In vitro cellular uptake by flow cytometry indicated the better uptake final product into the MCF-7 cells. The detection of apoptosis induced cell death was confirmed by RT-PCR. Conclusion: This study has created a prospective pathway for targeting cancer cells using chitosan.

Sign in / Sign up

Export Citation Format

Share Document